News
November 14, 2017
Toronto, November 14, 2017 – Brand-name drug companies’ research and development spending as a percentage of sales in Canada is less than half of the 10% the industry committed to when their periods of market exclusivity were increased in 1987, according to the most recent annual report from the federal government’s Patented Medicine Prices Review Board (PMPRB).
October 2, 2017
Toronto, October 2, 2017 – The Canadian Generic Pharmaceutical Association (CGPA) is pleased to announce the election of Mr. Doug Sommerville, Senior Vice President and General Manager of Teva Canada, as Chair of CGPA, and, Jean-Guy Goulet, Chief Operating Officer of Pharmascience as Vice Chair of CGPA.
September 22, 2017
North American Generic and Biosimilar Medicines Industries Release Priorities for Renegotiation of NAFTA
September 21, 2017
Toronto, September 21, 2017 – The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), regarding today’s provisional application of the Comprehensive Economic and Trade Agreement (CETA) between Canada and the European Union, which includes extensive changes to Canada’s intellectual property regime for pharmaceuticals.
July 16, 2017
Montreal, July 16, 2017 – The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), regarding the Agreement in Principle announced today between the Government of Quebec and CGPA.
February 27, 2017
Toronto, February 27, 2017 – The Canadian Generic Pharmaceutical Association (CGPA) is pleased to announce the election of Mr. Larry MacGirr, Chief Operating Officer of Pharmascience, as Chair of CGPA, and Mr. Doug Sommerville, Senior Vice President and General Manager of Teva Canada, as Vice Chair of CGPA.
February 17, 2017
Toronto, February 17, 2017 - The Joint 23rd Medicines for Europe and 20th IGBA Annual Conference will unite over 300 experts from the generic and biosimilar sector to provide market trends, innovative commercial strategies, new updates and opportunities for growth for affordable medicines.